Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines.

Francesco Bellinato, Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Author Information
  1. Francesco Bellinato: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126 Verona, Italy. ORCID
  2. Martina Maurelli: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126 Verona, Italy. ORCID
  3. Paolo Gisondi: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126 Verona, Italy. ORCID
  4. Giampiero Girolomoni: Section of Dermatology and Venereology, Department of Medicine, University of Verona, Piazzale A. Stefani 1, 37126 Verona, Italy. ORCID

Abstract

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30-70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

Keywords

References

  1. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e741-e743 [PMID: 34310763]
  2. JAAD Case Rep. 2021 Jul;13:30-32 [PMID: 33997209]
  3. Vis J Emerg Med. 2021 Oct;25:101108 [PMID: 34423142]
  4. Clin Exp Dermatol. 2021 Dec;46(8):1615-1617 [PMID: 34081806]
  5. Clin Exp Dermatol. 2021 Aug;46(6):1131-1134 [PMID: 33835617]
  6. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e847-e850 [PMID: 34363637]
  7. Front Med (Lausanne). 2021 May 14;8:664179 [PMID: 34055838]
  8. Vaccine. 2016 Dec 12;34(51):6634-6640 [PMID: 26392009]
  9. Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):957-961 [PMID: 33677050]
  10. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e857-e859 [PMID: 34363647]
  11. Br J Dermatol. 2021 Jul;185(1):e3 [PMID: 33904168]
  12. Dermatol Online J. 2021 Jan 15;27(1): [PMID: 33560802]
  13. J Eur Acad Dermatol Venereol. 2021 Aug 20;: [PMID: 34416052]
  14. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e548-e551 [PMID: 34021625]
  15. Int J Risk Saf Med. 2021;32(4):261-264 [PMID: 34420983]
  16. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e737-e738 [PMID: 34310755]
  17. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211024431 [PMID: 34120504]
  18. JAAD Case Rep. 2021 Sep;15:67-68 [PMID: 34337117]
  19. J Am Acad Dermatol. 2021 Jul;85(1):46-55 [PMID: 33838206]
  20. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e543-e545 [PMID: 34048614]
  21. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e546-e548 [PMID: 33982814]
  22. BMJ Case Rep. 2021 Jul 26;14(7): [PMID: 34312136]
  23. Int J Infect Dis. 2021 May;106:376-381 [PMID: 33866000]
  24. Am J Case Rep. 2021 Jul 21;22:e931478 [PMID: 34285180]
  25. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e846-e847 [PMID: 34363257]
  26. J Eur Acad Dermatol Venereol. 2021 Jun;35(6):e362-e365 [PMID: 33752263]
  27. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e645-e647 [PMID: 34169578]
  28. JAAD Case Rep. 2021 Jul;13:134-137 [PMID: 34056055]
  29. J Cutan Pathol. 2021 Jul 22;: [PMID: 34292611]
  30. J Cosmet Dermatol. 2021 Sep;20(9):2684-2690 [PMID: 34174156]
  31. J Drugs Dermatol. 2021 Aug 1;20(8):898-900 [PMID: 34397201]
  32. Cureus. 2021 Aug 16;13(8):e17215 [PMID: 34540442]
  33. N Engl J Med. 2021 Apr 1;384(13):1273-1277 [PMID: 33657292]
  34. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e845-e846 [PMID: 34363717]
  35. JAAD Case Rep. 2021 Oct;16:53-57 [PMID: 34423106]
  36. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e727-e729 [PMID: 34236728]
  37. Lancet. 2021 Jun 26;397(10293):e19 [PMID: 34126043]
  38. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):e483-e485 [PMID: 33834563]
  39. Clin Exp Dermatol. 2021 Jul 8;: [PMID: 34236711]
  40. J Dermatolog Treat. 2018 Dec;29(8):831-834 [PMID: 29671656]
  41. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e716-e717 [PMID: 34236729]
  42. Drugs R D. 2021 Dec;21(4):371-374 [PMID: 34351606]
  43. Int J Dermatol. 2021 Sep;60(9):1150-1151 [PMID: 34110010]
  44. Inflamm Res. 2021 Sep;70(9):935-937 [PMID: 34390376]
  45. J Thromb Haemost. 2021 Sep;19(9):2314-2317 [PMID: 34105247]
  46. Mult Scler. 2021 Dec;27(14):2291-2292 [PMID: 34100306]
  47. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e868-e870 [PMID: 34416044]
  48. Arch Dermatol Res. 2021 Feb 9;: [PMID: 33559733]
  49. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e864-e865 [PMID: 34416058]
  50. Clin Exp Dermatol. 2021 Oct;46(7):1325-1327 [PMID: 33914926]
  51. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2499-2504 [PMID: 32585074]
  52. N Engl J Med. 2021 Aug 12;385(7):662-664 [PMID: 34126004]
  53. J Infect Public Health. 2021 Oct;14(10):1392-1394 [PMID: 34294590]
  54. Cureus. 2021 Apr 13;13(4):e14453 [PMID: 33996313]
  55. Clin Exp Dermatol. 2021 Aug 11;: [PMID: 34379821]
  56. N Engl J Med. 2021 Feb 18;384(7):643-649 [PMID: 33378605]
  57. J Travel Med. 2021 Jun 1;28(4): [PMID: 33620081]
  58. Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):835-836 [PMID: 34153381]
  59. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e752-e755 [PMID: 34309932]
  60. Nat Rev Immunol. 2021 Apr;21(4):195-197 [PMID: 33674759]
  61. J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e841-e845 [PMID: 34363713]
  62. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e733-e735 [PMID: 34243220]
  63. Allergy Asthma Immunol Res. 2021 Jul;13(4):526-544 [PMID: 34212542]
  64. J Infect Public Health. 2021 Oct;14(10):1389-1391 [PMID: 34391695]
  65. J Allergy Clin Immunol. 2021 Sep;148(3):750-751 [PMID: 34275656]
  66. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e632-e634 [PMID: 34131967]
  67. Br J Dermatol. 2021 Jul 13;: [PMID: 34254291]
  68. Allergy Rhinol (Providence). 2021 Jun 24;12:21526567211026271 [PMID: 34249404]
  69. JAMA Dermatol. 2021 Aug 1;157(8):1000-1002 [PMID: 34160555]
  70. Case Rep Dermatol. 2021 Aug 18;13(2):432-436 [PMID: 34594203]
  71. Acta Med Indones. 2021 Jul;53(3):326-330 [PMID: 34611073]
  72. Clin Exp Dermatol. 2021 Aug 16;: [PMID: 34398977]
  73. Allergy. 2021 Aug;76(8):2605-2607 [PMID: 33811344]
  74. J Allergy Clin Immunol Pract. 2021 Jun;9(6):2139-2144 [PMID: 33831618]
  75. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e649-e651 [PMID: 34169588]
  76. Int J Dermatol. 2021 Aug;60(8):1032-1033 [PMID: 33928638]
  77. Adv Drug Deliv Rev. 2021 May;172:314-338 [PMID: 33482248]
  78. Immunol Allergy Clin North Am. 2014 Aug;34(3):597-613, ix [PMID: 25017679]
  79. Toxicol Rep. 2021;8:871-879 [PMID: 33898273]
  80. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e425-e427 [PMID: 33783873]
  81. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):e560-e563 [PMID: 34036651]
  82. JAAD Case Rep. 2021 Sep;15:11-14 [PMID: 34337124]
  83. Int J Dermatol. 2021 Sep;60(9):1152-1153 [PMID: 33900629]

Grants

  1. Impact of COVID19 infection on patients affected by inflammatory skin diseases on immunosuppressive therapies (COVISKIN); ID 1833073 rif. 2020-1363./Fondazione Cariplo

Word Cloud

Created with Highcharts 10.0.0reactionsSARS-CoV-2adversecutaneousvaccinationsassociatedmorphologicalpatternsvaccinescommonCutaneousreportedreviewedaccordingclinicalfollowingonsetmanifestationsdermatosesgenerallymildcasedermatitisCOVID-19ManypatientsreceivingvarietyeffectsprogressivelyobjectivereviewsummarizeexistingdataconcerninggrouppathogeneticEnglishlanguageliterature15August2021usingpredefinedkeywordsidentifyrelevantstudiesevaluatingsearchrecurrentsharingsignssymptomsphysio-pathologicalmechanismsTimingfirstboosterdosevaccinepredisposingconditionstherapeuticmanagementoutcomealsocollectedAmongdermatologicaldistinguished:1new2flarespreexistinginjectionsiteaffecting30-70%moderateSmallseriessinglereportsincludedfillerexanthemasvascularlesionsurticariaeczematousautoimmunebulloussevereadditionexacerbationchronicimmuno-mediatedmainlypsoriasisatopicreactivationsherpesinfectionself-limitingresembleddrugeruptionsand/orskinAdverseReactionsAssociatedVaccinesreactionexanthemasafety

Similar Articles

Cited By